CA2874507A1 - Biomarkers and uses thereof in methods of determining the effectiveness of treatment for diabetes - Google Patents

Biomarkers and uses thereof in methods of determining the effectiveness of treatment for diabetes Download PDF

Info

Publication number
CA2874507A1
CA2874507A1 CA2874507A CA2874507A CA2874507A1 CA 2874507 A1 CA2874507 A1 CA 2874507A1 CA 2874507 A CA2874507 A CA 2874507A CA 2874507 A CA2874507 A CA 2874507A CA 2874507 A1 CA2874507 A1 CA 2874507A1
Authority
CA
Canada
Prior art keywords
cell
central memory
sample
level
ratio
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2874507A
Other languages
English (en)
French (fr)
Inventor
Tihamer Orban
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phaim Pharma Ltd
Original Assignee
Orban Biotech LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orban Biotech LLC filed Critical Orban Biotech LLC
Publication of CA2874507A1 publication Critical patent/CA2874507A1/en
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Ecology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA2874507A 2012-05-24 2013-05-24 Biomarkers and uses thereof in methods of determining the effectiveness of treatment for diabetes Pending CA2874507A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261651144P 2012-05-24 2012-05-24
US61/651,144 2012-05-24
PCT/US2013/042627 WO2013177505A1 (en) 2012-05-24 2013-05-24 Diabetes biomarkers

Publications (1)

Publication Number Publication Date
CA2874507A1 true CA2874507A1 (en) 2013-11-28

Family

ID=49621783

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2874507A Pending CA2874507A1 (en) 2012-05-24 2013-05-24 Biomarkers and uses thereof in methods of determining the effectiveness of treatment for diabetes

Country Status (13)

Country Link
US (5) US20130316375A1 (enExample)
EP (2) EP3767295A1 (enExample)
JP (5) JP6312332B2 (enExample)
KR (1) KR102172285B1 (enExample)
CN (1) CN104520707B (enExample)
AU (4) AU2013266145A1 (enExample)
CA (1) CA2874507A1 (enExample)
DK (1) DK2856149T3 (enExample)
ES (1) ES2810227T3 (enExample)
IN (1) IN2014DN10259A (enExample)
MX (1) MX357169B (enExample)
WO (1) WO2013177505A1 (enExample)
ZA (1) ZA201409006B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8735359B2 (en) 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes
US20130316375A1 (en) * 2012-05-24 2013-11-28 Orban Biotech Llc Diabetes biomarkers
CN113138279A (zh) 2012-06-27 2021-07-20 法姆制药有限责任公司 融合蛋白组合物的应用
GB2523399B (en) 2014-02-25 2019-03-13 Orban Tihamer A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence
WO2016103390A1 (ja) * 2014-12-25 2016-06-30 株式会社日立製作所 インスリン分泌能分析装置、当該装置を備えるインスリン分泌能分析システム及びインスリン分泌能分析方法
CN105567851A (zh) * 2016-02-29 2016-05-11 北京泱深生物信息技术有限公司 一种与糖尿病相关的分子标志物
EP3433612B1 (en) * 2016-03-22 2024-10-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits of assessing status, risk or prognosis of type 1 diabetes
CA3184157A1 (en) 2020-06-26 2021-12-30 Phaim Pharma Ltd Psoriasis and other autoimmune diseases antigen immune modulator (aim) therapeutic platform
US20240277768A1 (en) 2021-06-17 2024-08-22 Tihamer Orban Individualized Cell Therapy Using Patient-Derived Antigen-Specific Regulatory T Cells

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1930415A4 (en) * 2005-09-30 2009-05-13 Univ Kyoto DEVELOPMENT OF A SCREENING METHOD FOR A CONNECTABLE COMPOUND FOR IMPROVING THE PRODUCTION OF A REGULATORY T-CELL AND METHOD FOR THE PRODUCTION OF A REGULATORY T-CELL USING AN IMMUNOSUPPRESSIVE MAKROLIDANTIBIOTIC
US9176122B2 (en) * 2008-03-24 2015-11-03 University Of South Florida Biomarkers for predicting response to immunosuppressive therapy
US20100080784A1 (en) * 2008-09-12 2010-04-01 Torrey Pines Institute For Molecular Studies Methods for treating cachexia and lymphopenia
US20130316375A1 (en) * 2012-05-24 2013-11-28 Orban Biotech Llc Diabetes biomarkers

Also Published As

Publication number Publication date
KR20150022878A (ko) 2015-03-04
JP2018116061A (ja) 2018-07-26
CN104520707A (zh) 2015-04-15
AU2019200824B2 (en) 2021-06-24
EP2856149A1 (en) 2015-04-08
US20160299128A1 (en) 2016-10-13
MX357169B (es) 2018-06-28
AU2019200824A1 (en) 2019-04-04
JP2024150702A (ja) 2024-10-23
JP6312332B2 (ja) 2018-04-18
AU2021202609A1 (en) 2021-05-27
JP6761827B2 (ja) 2020-09-30
EP3767295A1 (en) 2021-01-20
US20230333094A1 (en) 2023-10-19
EP2856149A4 (en) 2016-06-01
IN2014DN10259A (enExample) 2015-08-07
MX2014014348A (es) 2015-06-05
JP2021001899A (ja) 2021-01-07
KR102172285B1 (ko) 2020-11-02
US20130316375A1 (en) 2013-11-28
EP2856149B1 (en) 2020-07-08
JP2015520378A (ja) 2015-07-16
DK2856149T3 (da) 2020-08-17
AU2013266145A1 (en) 2015-01-15
ES2810227T3 (es) 2021-03-08
US20250237643A1 (en) 2025-07-24
JP2023011814A (ja) 2023-01-24
CN104520707B (zh) 2018-03-27
ZA201409006B (en) 2016-07-27
US20190137483A1 (en) 2019-05-09
WO2013177505A1 (en) 2013-11-28
AU2023222980A1 (en) 2023-09-21

Similar Documents

Publication Publication Date Title
US20250237643A1 (en) Diabetes Biomarkers
US20240210393A1 (en) Detection and treatment of autoimmune disorders
Herold et al. β cell death and dysfunction during type 1 diabetes development in at-risk individuals
Gaowa et al. Effect of Th17 and Treg axis disorder on outcomes of pulmonary arterial hypertension in connective tissue diseases
US10914743B2 (en) Kit for diagnosis, prognosis, and monitoring the immune status, of patients with chronic inflammatory diseases
US20190321448A1 (en) Insulin Mimotopes and Methods of Using the Same
Tizazu et al. Low rate of glutamic acid decarboxylase 65 (GAD-65) antibodies in chronic epilepsy
Bollyky et al. Type 1 diabetes mellitus: primary, secondary, and tertiary prevention
Xiang et al. Expression of Th17 and C [D. sup. 4+] C [D. sup. 25+] T regulatory cells in peripheral blood of acute leukemia patients and their prognostic significance
Burlingham et al. Delayed type hypersensitivity responses
Almeida Glycans as novel immunomodulators in Idiopathic Inflammatory Myopathies
Hill Immunomodulatory responses in the pancreas in health and disease
Boubacar et al. Myasthenia Gravis Associated with Diabetes about an Observation in Dakar, Senegal (West Africa) and Review of the Literature
Ragogna Combined unsupervised and semi-automated supervised analysis of flow cytometry data reveals cellular fingerprint associated with newly diagnosed pediatric type 1 diabetes
Burmester Prefectural University); S. Kumagai (Kobe University); H. Wakabayashi (Okayama University); E. Suematsu (NHO Kyusyu Medical Center); T. Fukuda (Kurume University)
Franzese et al. T1D PROGRESSION IS ASSOCIATED WITH LOSS OF CD3+ CD56+ REGULATORY CELLS

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180524

EEER Examination request

Effective date: 20180524

EEER Examination request

Effective date: 20180524

EEER Examination request

Effective date: 20180524

EEER Examination request

Effective date: 20180524

EEER Examination request

Effective date: 20180524

EEER Examination request

Effective date: 20180524

EEER Examination request

Effective date: 20180524

EEER Examination request

Effective date: 20180524